AnaSpec has introduced the SensoLyte 390 ACE2 activity assay kit - said to be the industry's first assay kit for the continuous monitoring of ACE2 activity
With its reported relation to cardiovascular disease, kidney disease, and severe acute respiratory syndrome (Sars), Angiotensin I converting enzyme 2 (ACE2) has become an increasingly important therapeutic target.
ACE2 is a zinc metallopeptidase that plays a central role in the control of angiotensin peptides.
ACE2 has direct effects on cardiac function, and is expressed predominantly in vascular endothelial cells of the heart and the kidneys.
It has been reported that ACE2 might protect kidneys in early stages of diabetes.
In addition to its role in the regulation of hypertension, ACE2 is a functional receptor for the coronavirus that causes severe acute respiratory syndrome (SARS).
Using a Mc-Ala/Dnp fluorescence resonance energy transfer (Fret) peptide, the SensoLyte 390 ACE2 activity assay kit provides a convenient assay for high throughput screening of ACE2 inhibitors and inducers and for continuous assay of ACE2 activity.
In the intact Fret peptide the fluorescence of Mc-Ala is quenched by Dnp.
Upon cleavage into two separate fragments by ACE2, the fluorescence of Mc-Ala is recovered, and can be monitored at excitation/emission =330/390nm.
Performed in a convenient 96-well microplate, the assay can detect the activity of subnanogram levels of ACE2.
